Sarepta Therapeutics (SRPT)
$124.95 2.98 (2.44%)
19:16 EDT SRPT Stock Quote Delayed 15 Minutes
Previous Close $124.95
Market Cap 8.19B
PE Ratio -42.50
Volume (Avg. Vol.) 1.24M
Day's Range 123.12 - 126.19
52-Week Range 95.21 - 165.87
Dividend & Yield N/A (N/A)
SRPT Stock Predictions, Articles, and Sarepta Therapeutics News
- From InvestorPlace
- From the Web
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
If you’re looking for a quick portfolio boost, look no further. Here are 7 stocks to buy with tons of upside according to top analysts.
If you follow the smart money, you end up following these stocks to buy. Here's what you should know about each.
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
Sarepta Therapeutics (SRPT) stock is sinking after the company's late Tuesday announcement that it was offering a $350 million stock ofering.
SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.
Sarepta used the lobbying of patient families to win approval of a drug that may not work against Duchenne muscular dystrophy. It may be time to take profits in SRPT stock..
What's the next big thing in biotech? The answer is gene therapy and these five biotech stocks are leading the way.
According to Wall Street, these 7 stellar strong buy stock picks all boast over 30% upside potential from their current prices.
Here we dig down into seven intriguing stock rating upgrades from the Street. Why now? Why are analysts turning bullish on these stocks? All seven of these stocks share a 'Strong Buy' analyst consensus rating from the Street. The result: you can be confident that these stocks are the crème de la crème.
Sarepta Therapeutics (SRPT) stock was hit hard on Friday after reports claim one of its studies was put on hold due to an adverse event.
Sarepta Therapeutics (SRPT) stock was flying high on Thursday following the release of its earnings report for the second quarter of 2017.
Sarepta Therapeutics Inc (SRPT) stock was up on Thursday following an upgrade and price target increase from Leerink Swann.
These five biotech stocks are among some of the hottest movers as investors start 2017 with a rush into healthcare.
Biotech stocks and the SPDR S&P Biotech ETF (XBI) just shook off a major bugaboo in Hillary Clinton. The XBI ETF will soar as a result.
From Analyst Ratings
Yesterday it was reported that the EVP, CFO & CBO of Sarepta Therapeutics (SRPT – Research Report), Sandesh Mahatme, exercised options to buy 9,754 SRPT shares at $24.73 a share, for a total transaction value of $241.2K. Following Sandesh Mahatme’s last SRPT Buy transaction on November 10, 2016, the stock climbed by 81.0%. Following this
From Analyst Ratings
Today, a Director at Sarepta Therapeutics (SRPT – Research Report), Richard Barry, bought shares of SRPT for $453.3K. In addition to Richard Barry, one other SRPT executive reported Buy trades in the last month. See today’s analyst top recommended stocks >> Based on Sarepta Therapeutics’ latest earnings report for the quarter ending June 30, the
From Market News Video
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!